Clinical trial
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK…
NCT00465816 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00465816 |
|---|---|
| Title | Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 |
| Official title | Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Nimenrix (Meningococcal vaccine 134612), Twinrix |
| Enrollment | 611 |
| Start date | Apr 11, 2007 |
| Primary completion | Apr 28, 2008 |
| Completion | Apr 28, 2008 |
| First posted | Apr 25, 2007 |
| Last update posted | Jun 8, 2018 |
| Countries | Denmark, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: